Today: 14 May 2026
Browse Category

ASX:BXB.AX 19 February 2026

Stock Market Today

  • Phillips 66 (PSX) Sets Ex-Dividend Date for May 18, 2026
    May 14, 2026, 10:46 AM EDT. Phillips 66 (PSX) will trade ex-dividend on May 18, 2026, offering a quarterly payout of $1.27 per share. This dividend represents approximately 0.73% of PSX's recent $173.01 stock price. The dividend, payable June 1, 2026, suggests shares may open lower by about 0.73% on the ex-dividend date, assuming all other factors remain steady. PSX shares have traded between $109.75 and $190.61 over the past 52 weeks and closed recently near $172.62. The stock currently yields an annualized 2.94% dividend. Representing 7.02% of the VanEck Oil Refiners ETF (CRAK), PSX was up roughly 0.7% in Thursday trading, while CRAK edged down 0.2%. Investors monitor such moves closely for income-focused opportunities amid market volatility.

Latest articles

IREN Stock Rises as $2.6 Billion Debt Deal Tests Its Nvidia AI Ambitions

IREN Stock Rises as $2.6 Billion Debt Deal Tests Its Nvidia AI Ambitions

14 May 2026
IREN Limited shares climbed 4.7% to $57.75 in New York after the company priced $2.6 billion in 1.00% convertible senior notes due 2033, up from a $2 billion plan. The offering, expected to close May 14, follows a $3.4 billion AI cloud services contract and a strategic partnership with Nvidia. IREN reported a $247.8 million net loss for the March quarter. JPMorgan raised its price target to $46 but maintained an Underweight rating.
Redwire Stock Jumps Again as $498 Million Backlog Puts Defense Growth Back in Play

Redwire Stock Jumps Again as $498 Million Backlog Puts Defense Growth Back in Play

14 May 2026
Redwire shares jumped nearly 14% to $13.04 Thursday after reporting first-quarter revenue up 57.9% to $97 million and reaffirming its 2026 sales outlook. The company ended March with a $498.1 million backlog but posted a $76.5 million net loss. Redwire also launched a $350 million at-the-market share program, raising dilution concerns.
Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over

Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over

14 May 2026
Biogen closed its $5.3 billion acquisition of Apellis Pharmaceuticals, making Apellis a wholly owned subsidiary and ending its Nasdaq listing. Apellis shareholders receive $41 per share in cash plus a contingent value right tied to Syfovre sales. Biogen gains Syfovre and Empaveli, which generated $689 million in 2025 revenue. Biogen funded the deal with $2 billion in unsecured term loans.
Intel Stock Falls Again as AMD and Arm Put Its Comeback Under Pressure

Intel Stock Falls Again as AMD and Arm Put Its Comeback Under Pressure

14 May 2026
Intel shares fell 3.9% to $115.55 Thursday after UBS data showed its server CPU market share dropped to 54.9% in Q1, down from 64.4% a year earlier, while AMD and Arm gained ground. The decline comes despite Intel reporting Q1 revenue of $13.6 billion and announcing a multi-year partnership with McLaren Racing.
Go toTop